Chinese firm gets approval to begin human testing for coronavirus vaccine

The potential vaccine has received a certificate from the National Medical Products Administration to launch clinical trials

vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab
Chinese researchers and companies are testing six experimental shots in humans
Reuters New Delhi
1 min read Last Updated : Jun 23 2020 | 3:02 PM IST
China has approved a coronavirus vaccine candidate developed by Chongqing Zhifei Biological Products' unit to begin human testing, the company said in a filing on Tuesday.

The potential vaccine, co-developed by Anhui Zhifei Longcom Biopharmaceutical and the Institute of Microbiology of the Chinese Academy of Sciences, has received a certificate from the National Medical Products Administration to launch clinical trials.

Chinese researchers and companies are testing six experimental shots in humans, and more than a dozen vaccines are in different stages of clinical trials globally against the virus that has killed over 470,000 people.


However, none of the them have passed large-scale, late-stage phase 3 clinical trials, a necessary step before entering the consumer market.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusChinapharmaceutical sectorclinical trialsCoronavirus Vaccine

Next Story